These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9014749)

  • 61. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb.
    Lingam MK; Byrne DS; Aitchison T; MacKie RM; McKay AJ
    Eur J Cancer; 1996 Sep; 32A(10):1668-73. PubMed ID: 8983272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma.
    Taber SW; Polk HC
    Ann Surg Oncol; 1997; 4(5):440-5. PubMed ID: 9259973
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability.
    Guadagni S; Palumbo G; Fiorentini G; Clementi M; Marsili L; Giordano AV; Masedu F; Valenti M
    BMC Res Notes; 2017 Aug; 10(1):411. PubMed ID: 28810925
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat.
    Roberts MS; Wu ZY; Siebert GA; Thompson JF; Smithers BM
    Melanoma Res; 2001 Dec; 11(6):611-8. PubMed ID: 11725207
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination.
    Lejeune FJ; Ghanem GE
    Cancer Res; 1987 Jan; 47(2):639-43. PubMed ID: 3791248
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?
    Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; van Dongen JA
    Melanoma Res; 1994 Mar; 4 Suppl 1():13-6. PubMed ID: 8038589
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
    Thompson JF; Lai DT; Ingvar C; Kam PC
    Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.
    Würl P; Eichfeld U; Pauer HD; Gläser A; Rose U; Dralle H
    Surg Today; 1997; 27(8):719-25. PubMed ID: 9306586
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of an automated circuit for isolated limb infusion for malignancy.
    Grobmyer SR; Filichia L; Robinson AR; Clark TD; Vaughn K; Copeland EM; Hochwald SN
    Eur J Surg Oncol; 2010 Dec; 36(12):1215-9. PubMed ID: 20947288
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Successful treatment of in-transit metastases from Merkel's cell carcinoma with isolated hyperthermic limb perfusion.
    Gupta AS; Heinzman S; Levine EA
    South Med J; 1998 Mar; 91(3):289-92. PubMed ID: 9521375
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Complete remission of advanced cutaneous leiomyosarcoma following isolated limb perfusion with high-dose tumour necrosis factor-alpha and melphalan.
    Häffner AC; Zepter K; Fritz T; Dummer R; Lejeune FJ; Burg G
    Br J Dermatol; 1999 Nov; 141(5):935-6. PubMed ID: 10583188
    [No Abstract]   [Full Text] [Related]  

  • 72. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
    Klaase JM; Kroon BB; Beijnen JH; van Slooten GW; van Dongen JA
    Br J Cancer; 1994 Jul; 70(1):151-3. PubMed ID: 8018528
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study.
    Kroon HM; Coventry BJ; Giles MH; Henderson MA; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Smithers BM; Thompson JF
    Ann Surg Oncol; 2017 Oct; 24(11):3245-3251. PubMed ID: 28799064
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
    Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
    Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
    Di Filippo F; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S
    Tumori; 2003; 89(4 Suppl):241-3. PubMed ID: 12903606
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.
    Wieberdink J; Benckhuysen C; Braat RP; van Slooten EA; Olthuis GA
    Eur J Cancer Clin Oncol; 1982 Oct; 18(10):905-10. PubMed ID: 6891640
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.
    Pigozzo J; De Rossi C; Rossi CR; Nitti D; Sileni VC
    Melanoma Res; 2009 Jun; 19(3):193-4. PubMed ID: 19436179
    [No Abstract]   [Full Text] [Related]  

  • 78. TNF dose reduction in isolated limb perfusion.
    Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
    Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
    Santillan AA; Zager JS
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
    [No Abstract]   [Full Text] [Related]  

  • 80. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
    Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
    Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.